Dear Colleagues,

Alzheimer’s disease (AD) is an age-related neurological disorder, the most common cause form of dementia, and a top 10 cause of death. On average, affected individuals live seven years after diagnosis. In most cases, the primary caretakers are immediate family members, frequently an unaffected, elderly, spouse. In the past 20 years, the number of AD deaths has more than doubled, and the incidence of AD is expected to continue its rapid increase. Despite significant efforts, there are currently no disease-altering treatments, and relatively few clinical trials underway.

AD begins many years before the onset of symptoms. A hallmark pathology of AD is the accumulation of Aβ fragments in the brain, one of which leads to neuronal death. Amyloid precursor protein (APP) is cleaved by α- and β-secretases to create different Aβ fragments, one of which, Aβ₄₂, self-aggregates creating toxic plaques in the brain.

In the past 10 years, significant progress has been made towards solving the genetic architecture of AD. More than 20 different genes have been implicated in genome-wide association studies (GWAS), the majority of which are not functional and have relatively small effects on risk for disease. More recently, numerous rare genomic variants have been reported that influence risk for AD. These rare variants have a large effect on risk for disease and are more likely to be functional.

In this Special Issue of Genes, we extend an invitation for reviews on the current state of genetics and genomics in Alzheimer’s Disease, as well as original research articles. We are especially interested in contributions that utilize novel methods, describe protective variants, consider alternative hypotheses to AD, or contribute to our ability to diagnose AD early. However, we will consider any manuscript describing the genomics of AD.

Dr. Perry G. Ridge
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Alzheimer’s disease
• AD
• genetic markers
• genome sequencing
• neurological disorder